CA2931023C - Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer - Google Patents

Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer Download PDF

Info

Publication number
CA2931023C
CA2931023C CA2931023A CA2931023A CA2931023C CA 2931023 C CA2931023 C CA 2931023C CA 2931023 A CA2931023 A CA 2931023A CA 2931023 A CA2931023 A CA 2931023A CA 2931023 C CA2931023 C CA 2931023C
Authority
CA
Canada
Prior art keywords
cancer
seq
peptide
amino acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2931023A
Other languages
English (en)
French (fr)
Other versions
CA2931023A1 (en
Inventor
Yoram Devary
Uziel Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune System Key Ltd
Original Assignee
Immune System Key Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Key Ltd filed Critical Immune System Key Ltd
Publication of CA2931023A1 publication Critical patent/CA2931023A1/en
Application granted granted Critical
Publication of CA2931023C publication Critical patent/CA2931023C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2931023A 2013-12-05 2014-12-04 Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer Active CA2931023C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (2)

Publication Number Publication Date
CA2931023A1 CA2931023A1 (en) 2015-06-11
CA2931023C true CA2931023C (en) 2023-12-19

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931023A Active CA2931023C (en) 2013-12-05 2014-12-04 Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer

Country Status (11)

Country Link
US (1) US9878015B2 (https=)
EP (1) EP3076988B1 (https=)
JP (1) JP6609556B2 (https=)
KR (1) KR102384795B1 (https=)
CN (1) CN105939724B (https=)
AU (1) AU2014358671B2 (https=)
CA (1) CA2931023C (https=)
DK (1) DK3076988T3 (https=)
ES (1) ES2742856T3 (https=)
IL (1) IL245998B (https=)
WO (1) WO2015083167A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411711B1 (en) 2016-02-04 2022-08-03 Immune System Key Ltd. Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
KR20250004754A (ko) * 2022-04-11 2025-01-08 이뮨 시스템 키 엘티디. 증식성 질환의 치료를 위한 bcl2 억제제 및 펩티드 병용 요법
JP7843546B2 (ja) * 2022-05-27 2026-04-10 ジンキュア・コーポレイション 新規なペプチド及びその用途
CN121443625A (zh) * 2023-05-03 2026-01-30 免疫系统密钥有限公司 环状d-肽、其衍生物、组合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507094T3 (es) * 2004-10-25 2014-10-14 Immune System Key Ltd. Proteína específica del timo
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Also Published As

Publication number Publication date
KR102384795B1 (ko) 2022-04-08
CA2931023A1 (en) 2015-06-11
US9878015B2 (en) 2018-01-30
IL245998B (en) 2019-12-31
KR20160085361A (ko) 2016-07-15
EP3076988B1 (en) 2019-06-05
JP2017505755A (ja) 2017-02-23
ES2742856T3 (es) 2020-02-17
AU2014358671B2 (en) 2019-09-12
WO2015083167A1 (en) 2015-06-11
IL245998A0 (en) 2016-07-31
CN105939724A (zh) 2016-09-14
EP3076988A1 (en) 2016-10-12
DK3076988T3 (da) 2019-09-16
JP6609556B2 (ja) 2019-11-20
CN105939724B (zh) 2020-01-14
AU2014358671A1 (en) 2016-06-02
US20160303200A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
UA123392C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу, та його застосування для лікування раку
US20160296604A1 (en) Peptide Having Angiogenesis Inhibitory Activity and Composition Containing Same
US20150038429A1 (en) Etoposide and doxorubicin conjugates for drug delivery
KR20200100866A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
JP6104872B2 (ja) 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
EP2931265B3 (en) Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
JP2022023215A (ja) Ｄｐｅｐ－１結合組成物および使用の方法
CA2931023C (en) Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer
US20220048973A1 (en) B1SP Fusion Protein Therapeutics, Methods, and Uses
US20150183826A1 (en) CD44V6-Derived Peptides for Treating Metastasizing Cancer
US20150071855A1 (en) Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
CN117062842A (zh) 新型双环肽
US20250134975A1 (en) Cancer vaccine comprising epitope of c-met and use thereof
WO2026022392A1 (en) Peptide and conjugates thereof
AU2024351102A1 (en) Treatment of cancers associated with beta-catenin
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド
TW201545754A (zh) 用於抑制骨髓衍生抑制細胞之組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241113

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118